Lung Cancer
Conditions
Brief summary
The investigators previously validated the grading system proposed by International Association for the Study of Lung Cancer (IASLC) for invasive nonmucinous lung adenocarcinoma (LADC) for its reproducibility, prognostication function and predictive value of adjuvant chemotherapy (ACT). In this exploratory study, the investigators aimed to investigate the role of IASLC grading system in EGFR tyrosine kinase inhibitor (TKI) therapy selection either as adjuvant or palliative therapy.
Interventions
DIAGNOSTIC_TESTIASLC grading system
A cohort of 2160 patients with invasive nonmucinous EGFR-mutant LADCs were retrospectively collected and classified according to the IASLC grading system. The role of IASLC grading system in EGFR tyrosine kinase inhibitor (TKI) therapy selection either as adjuvant or palliative therapy was investigated.
Sponsors
Fudan University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* invasive lung adenocarcinoma patients who underwent complete resection with positive EGFR mutations in exons 18-21.
Exclusion criteria
* adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), invasive mucinous adenocarcinoma and other variants of adenocarcinoma * patients with pathologic slides unavailable for re-evaluation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival | 5 years | DFS was defined as time from initiation of surgery to date of first event (recurrence or death) |
| Progression-free survival | 5 years | PFS was defined as time from initiation of systemic palliative treatment to date of disease progression or death for 1L treatment of each patient and the initiation time was re-assigned additionally for each drug applied during the treatment history of the patients regardless of line of therapy (all lines) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 5 years | was defined as time from surgery to date of death resulting from any cause in ADJUVANT subgroup and from 1L systemic palliative treatment assignment to date of death resulting from any cause in RECURRENCE subgroup. |
Countries
China
Outcome results
None listed